NYSE:ABBVBiotechs
What Is AbbVie (ABBV) Poised To Gain From FDA Review Of New BOTOX Use?
AbbVie (NYSE:ABBV) said the FDA has accepted for review a supplemental Biologics License Application for BOTOX Cosmetic to treat masseter muscle prominence in the U.S.
The filing positions BOTOX Cosmetic as a potential first approved neurotoxin for this jawline contouring indication, expanding AbbVie’s facial aesthetics reach beyond wrinkle treatment.
AbbVie is seeking to build on Phase 3 data that supported efficacy and safety in adults seeking non surgical jawline contouring...